Neurocrine Biosciences
Executive Summary
Completes $30 mil. private placement managed by Kidder, Peabody & Co., Gruntal & Co., and D. Blech & Co. Neurocrine was formed in 1992 with seed financing of $3.5 mil. to develop drugs targeting "key signaling molecules responsible for integrating the nervous, endocrine and immune systems." The company has one compound for memory deficits in Alzheimer's patients in Phase II